Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDX012 in relapsed or refractory acute myeloid leukemia
jRCT2033240022Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2023
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label trial of allogeneic variable delta 1 gamma-delta T cells in acute myeloid leukemia (AML) (2 arms), sponsored by Takeda. Primary endpoints: Number of participants with dose-limiting toxicities to determine the maximum tolerated dose of GDX012 and Number of participants with treatment-emergent adverse events. Started Jul 2023; status: completed.
02
Drugs
allogeneic variable delta 1 gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2033240022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240022.